A Serum Protein Classifier Identifying Patients with Advanced Non-Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors.

Mirte MullerKarlijn HummelinkDaniel P HurkmansAnna-Larissa N NiemeijerKim MonkhorstJoanna RoderCarlos OliveiraHeinrich RoderJoachim G AertsEgbert F Smit

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

This serum-derived protein signature successfully stratified outcomes in cohorts of patients with advanced NSCLC treated with second-line PD-1 CPIs and deserves further prospective study.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
protein protein
small cell lung cancer
amino acid
binding protein
type diabetes
tyrosine kinase
newly diagnosed
smoking cessation
brain metastases